Teva and medincell receive complete response letter for tv-46000/mdc-irm

Parsippany, n.j. & tel aviv, israel & paris--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), and medincell (euronext: medcl) announced that the u.s. food and drug administration (“fda”) has issued a complete response letter (crl) regarding the new drug application (nda) for tv-46000/mdc-irm (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia. teva and medincell remain c
TEVA Ratings Summary
TEVA Quant Ranking